Sensei Biotherapeutics, Inc. (SNSE)

NASDAQ: SNSE · IEX Real-Time Price · USD
1.050
-0.030 (-2.78%)
At close: Apr 12, 2024, 4:00 PM
1.060
+0.010 (0.95%)
After-hours: Apr 12, 2024, 7:29 PM EDT
-2.78%
Market Cap 26.32M
Revenue (ttm) n/a
Net Income (ttm) -34.10M
Shares Out 25.07M
EPS (ttm) -1.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 31,885
Open 1.100
Previous Close 1.080
Day's Range 1.050 - 1.114
52-Week Range 0.510 - 1.926
Beta 0.16
Analysts Strong Buy
Price Target 4.00 (+280.95%)
Earnings Date May 7, 2024

About SNSE

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pip... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Feb 4, 2021
Employees 28
Stock Exchange NASDAQ
Ticker Symbol SNSE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for SNSE stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target
$4.0
(280.95% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

BOSTON, April 09, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer ...

4 days ago - GlobeNewsWire

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutic...

9 days ago - GlobeNewsWire

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutic...

22 days ago - GlobeNewsWire

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutic...

5 weeks ago - GlobeNewsWire

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade -

6 weeks ago - GlobeNewsWire

Sensei Biotherapeutics to Present at Upcoming Conferences

BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics...

2 months ago - GlobeNewsWire

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical milestones expected in 2024 -...

3 months ago - GlobeNewsWire

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

- SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported...

5 months ago - GlobeNewsWire

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

- Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encouraging cytokine release profile across multiple dose co...

5 months ago - GlobeNewsWire

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics...

5 months ago - GlobeNewsWire

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics...

6 months ago - GlobeNewsWire

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics...

6 months ago - GlobeNewsWire

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo®

- Eleven patients enrolled overall in trial to date, with enrollment progressing faster than anticipated - - Monotherapy arm has advanced to a fourth cohort, with initial monotherapy PK and safety dat...

7 months ago - GlobeNewsWire

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

- New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile -

7 months ago - GlobeNewsWire

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

BOSTON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutic...

7 months ago - GlobeNewsWire

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics...

8 months ago - GlobeNewsWire

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Phase 1/2 clinical trial enrolling for lead investigational candidate SNS-101, a conditionally active VISTA-blocking antibody for the treatment of advanced solid tumors

9 months ago - GlobeNewsWire

Sensei Biotherapeutics to Participate in Canaccord Genuity's 43rd Annual Growth Conference

BOSTON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics...

9 months ago - GlobeNewsWire

Sensei Biotherapeutics to Host Virtual Key Opinion Leader Event, “A New Vista for Cancer Care: Exploring SNS-101's Potential as a Transformative Treatment Option for Patients with Solid Tumors”

- Featuring Dr. James Gulley, Co-Director of the Center for Immuno-Oncology at the National Cancer Institute (NCI) and internationally recognized expert on cancer immunotherapy -

10 months ago - GlobeNewsWire

Sensei Biotherapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101, a Conditionally Active VISTA-blocking Antibody, for the Treatment of Advanced Solid Tumors

- Topline Phase 1 monotherapy and initial combination data expected in 2024 - BOSTON, June 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical-stage immuno-oncology co...

11 months ago - GlobeNewsWire

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

BOSTON, May 31, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics ...

11 months ago - GlobeNewsWire

Sensei Biotherapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights

- Investigational New Drug (IND) application for SNS-101 cleared by U.S. Food and Drug Administration (FDA) with first patient dose in Phase 1/2 trial expected in mid-2023 -

1 year ago - GlobeNewsWire

Sensei Biotherapeutics Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active VISTA-Blocking Antibody

First patient dose in the Phase 1/2 clinical trial expected in mid-2023 First patient dose in the Phase 1/2 clinical trial expected in mid-2023

1 year ago - GlobeNewsWire

Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023

BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer p...

1 year ago - GlobeNewsWire

Sensei Biotherapeutics to Participate in Cantor Fitzgerald's Future of Oncology Virtual Symposium

BOSTON, March 30, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer p...

1 year ago - GlobeNewsWire